University City Campus | CHOP Research Institute
 

University City Campus

This study involves taking a study drug called lurbinectedin. The overall goal of this study is to see if different doses of lurbinectedin are safe and effective at treating children and young adults with recurrent or relapsed solid tumors, including Ewing Sarcoma.

This study aims to design and optimize the Hypothyroidism Treatment Satisfaction Questionnaire (ThyTSQ) for measuring treatment satisfaction. 

Evaluate the impact of non-persistent and persistent chemical exposures on autoimmunity, gene expression and the microbiome in children with and without Crohn’s disease.

This study will determine the safety and usefulness of using the CliniMACS Prodigy platform to manufacture huCART19 cells.

The purpose of this study is to determine the safety and tolerability of an experimental form of therapy, known as UCART22 ("study drug").

The goal of this research study is to compare sex and gender development differences between children ages 4-8 years who are on the autism spectrum with children who are not on the autism spectrum.

We want to learn more about how the brains of children on the autism spectrum process sounds and language.

This study is being done to understand how the brain of autistic adolescents and adults process sound and language.  We hope the information gained from this study may lead to future therapies for language difficulties in autistic individuals.

Evaluate the safety and efficacy of an investigational drug called "Elamipretide" in adult patients with mitochondrial disease.

Study focusing on non-invasive MRI procedures to measure biological activity within leg muscles of individuals, including both healthy volunteers and those with mitochondrial disease.